In order to test whether compound 968 sensitized cancer cells to other anticancer drugs except erlotinib, gefitinib (the first selective inhibitor of EGFR) and cispatin (the first member of a class of platinum-containing anti-cancer drugs) were used for the evaluation. This evidence concerns the gene EGFR and cancer.